Nicotinic acetylcholine receptor ligands as potential therapeutics

Expert Opinion on Therapeutic Patents

Volumn 15, Issue 9, 2005, Pages 1221-1239

  Gündish, Daniela ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Alzheimer's disease; Epibatidine; Neurodegenerative disease; Nicotine; Nicotinic acetylcholine receptor (nAChR); Pain; Parkinson's disease

Indexed keywords

1,1 DIMETHYL 4 PHENYLPIPERAZINIUM IODIDE; ANTINOCICEPTIVE AGENT; AR R17779; BICYCLO[2.2.2]OCTANE DERIVATIVE; BICYCLO[3.2.0]HEPTANE DERIVATIVE; BICYCLO[3.2.1]OCTANE DERIVATIVE; BICYCLO[3.3.1]NONANE DERIVATIVE; BICYCLO[4.2.0]OCTANE DERIVATIVE; BORNEOL; CAMPHOR; CYCLOALKANE DERIVATIVE; GUANIDINE DERIVATIVE; INDOLE DERIVATIVE; N (4 ACETYL 1 PIPERAZINYL) 4 FLUOROBENZAMIDE; N METHYL 4 (3 PYRIDINYL) 3 BUTENAMINE; NICOTINE DERIVATIVE; NICOTINIC AGENT; NICOTINIC RECEPTOR; NORBORNANE DERIVATIVE; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE; QUINUCLIDINE DERIVATIVE; SSR 180711A; TACRINE; TETRAHYDROISOQUINOLINE DERIVATIVE; THIOUREA DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARENICLINE; VENLAFAXINE;

ALZHEIMER DISEASE; ANALGESIC ACTIVITY; ANTINOCICEPTION; ATTENTION DEFICIT DISORDER; CENTRAL NERVOUS SYSTEM DISEASE; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; EXCITATORY POSTSYNAPTIC POTENTIAL; HUMAN; IC 50; IN VITRO STUDY; NONHUMAN; PAIN; PARKINSON DISEASE; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SYNAPTIC TRANSMISSION; TOBACCO DEPENDENCE;

EID: 25444481876     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.15.9.1221     Document Type: Review

References (89)

1. ARNERIC SP, BRIONI JD (Eds): Neuronal Nicotinic Receptors. J. Wiley & Sons. New York (1999).
2. LUKAS RJ, CHANGEUX JP, NOVERE NL et al.: International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol. Rev. (1999) 51:397-401.
3. SARGENT PB: The diversity of neuronal nicotinic acetylcholine receptors. Ann. Rev. Neurosci. (1993) 16:403-443.
4. BERTRAND D, CHANGEUX JP: Nicotinic receptor: an allosteric protein specialized for intracellular communication. Semin. Neurosci. (1995) 7:75-90.
5. LE NOVÈRE N, CHANGEUX JP: Molecular evolution of the nicotinic acetylcholine receptor: an example of multigene family in excitable cells. J. Mol. Evol. (1995) 40:155-172.
6. 10 (CHRNA 10). Genomics (2001) 73:272-283.
7. CHANGEUX JP, EDELSTEIN SJ: Allosteric receptors after 30 years. Neuron (1998) 21:959-980.
8. BUNNELLE WH, DART MJ, SCHRIMPF MR: Design of ligands for the nicotinic acetylcholine receptors: the quest for selectivity. Curr. Topics Med. Chem. (2004) 4:299-334.
9. GRANDO SA: Biological functions of keratinocyte cholinergic receptors. J. Investig. Dermatol. Symp. Proc. (1997) 2:41-48.
10. MAUS AD, PEREIRA EF, KARACHUNSKI PI et al.: Human and rodent bronchial epithelial cells express functional nicotinic acetylcholine receptors. Mol. Pharmacol. (1998) 54:779-788.
11. NGUYEN VT, HALL LL, GALLACHER G et al.: Choline acetyltransferase, acetylcholinesterase, and nicotinic acetylcholine receptors of human gingival and esophageal epithelia. J. Dent. Res. (2000) 79:939-949.
12. SKOK MV, KALASHNIK EN, KOVAL LN et al.: Functional nicotinic acetylcholine receptors are expressed in B lymphocyte-derived cell lines. Mol. Pharmacol. (2003) 64:885-889.
13. 10: a determinant of nicotinic cholinergic receptor function in mammalian vestibular and cochlear mechanosensory hair cells. Proc. Natl. Acad. Sci. USA (2001) 98:3501-3506.
14. 10 nicotinic acetylcholine receptors revealed by heterologous expression of subunit chimeras. Mol. Pharmacol. (2004) 65:453-460.
15. 9: an acetylcholine receptor with novel pharmacological properties expressed in rat cochlear hair cells. Cell (1994) 79:705-715.
16. 4 nicotinic receptors show dopaminergic deficits and increased anxiety. Proc. Natl. Acad. Sci. USA (2001) 98:2786-2791.
17. PICCIOTTO MR, ZOLI M, LENA C et al.: Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain. Nature (1995) 374:65-67.
18. MARUBIO LM, DEL MAR ARROYO-JIMENEZ M et al.: Reduced antinociception in mice lacking neuronal nicotinic receptor subunits. Nature (1999) 398:805-810.
19. 4 neuronal nicotinic acetylcholine receptor subunit knock-out mouse. J. Neurosci. (2000) 20:6431-6441.
20. 6-containing nicotinic acetylcholine receptors analyzed with mutant mice. J. Neurosci. (2002) 22:1208-1217.
21. 3 neuronal nicotinic acetylcholine receptor. Proc. Natl. Acad. Sci. USA (1999) 96:5746-5751.
22. 5 neuronal nicotinic acetylcholine receptor subunit. J. Physiol. (2002) 542:347-354.
23. 7-containing neuronal nicotinic acetylcholine receptors does not prevent nicotine-induced seizures. Brain Res. Mol. Brain Res. (2002) 98:29-40.
24. 9 nicotinic ACh receptor subunits in the development and function of cochlear efferent innervation. Neuron (1999) 23:93-103.
25. 2 mutant mice. J. Neurosci. (1998) 18:4461-4472.
26. 4 subunits of neuronal nicotinic acetylcholine receptors. J. Neurosci. (1999) 19:9298-9305.
27. ZOLI M, PICCIOTTO MR, FERRARI R, COCCHI D, CHANGEUX JP: Increased neurodegeneration during ageing in mice lacking high-affinity nicotine receptors. EMBO (1999) 18:1235-1244.
28. 2 subunit are involved in the reinforcing properties of nicotine. Nature (1998) 391:173-177.
29. BOYD RT: The molecular biology of neuronal nicotinic acetylcholine receptors. Crit. Rev. Toxicol. (1997) 27:299-318.
30. LEWIS TM, HARKNESS PC, SIVILOTTI LG, COLQUHOUN D, MILLAR NS: The ion channel properties of a rat recombinant neuronal nicotinic receptor are dependent on the host cell type. J. Physiol. (1997) 1:299-306.
31. 2 nicotinic receptors. Brain Res. Mol. Brain Res. (2001) 96:68-76.
32. LENA C, CHANGEUX JP: Pathological mutations of nicotinic receptors and nicotine-based therapies for brain disorders. Curr. Opin. Neurobiol. (1997) 7:674-82.
33. JONES S, SUDWEEKS S, YAKEL JL: Nicotinic receptors in the brain: correlating physiology with function. Trends Neurosci. (1999) 22:555-561.
34. LLOYD GK, WILLIAMS M: Neuronal nicotinic acetylcholine receptors as novel drug targets. J. Pharmacol. Exp. Ther. (2000) 292:461-467.
35. PETO R, LOPEZ AD, BOREHAM J, THUN M, HEATH C JR, DOLL R: Mortality from smoking worldwide. Br. Med. Bull. (1996) 52:12-21.
36. HENNINGFIELD JE, MIYASATO K, JASINSKI DR: Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine. J. Pharmacol. Exp. Ther. (1985) 234:1-12.
37. DANI JA, JI D, ZHOU FM: Synaptic plasticity and nicotine addiction. Neuron (2001) 31:349-352.
38. GENTRY CL, LUKAS RJ: Regulation of nicotinic acetylcholine receptor numbers and function by chronic nicotine exposure. Curr. Drug Target CNS Neurol. Disord. (2002) 1:359-385.
39. TERRY AV, BUCCAFUSCO JJ: The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J. Pharmacol Exp. Ther. (2003) 306:821-827.
40. PERRY E, MARTIN-RUIZ C, LEE M et al.: Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. Eur. J. Pharmacol. (2000) 393:215-222.
41. 3H] nicotinic acetylcholine binding in Alzheimer's disease and Parkinson's disease: an autoradiographic study. Neurology (1988) 38:720-723.
42. SCHRÖDER H, GIACOBINI E, STRUBLE RG, ZILLES K, MAELICKE A: Nicotinic cholinoceptive neurons of the frontal cortex are reduced in Alzheimer's disease. Neurobiol. Aging (1991) 12:259-262.
43. QUIK M, JEYARASASINGAM G: Nicotinic receptors and Parkinson's disease. Eur. J. Pharmacol. (2000) 393:223-230.
44. QUIK M: Smoking, nicotine and Parkinson's disease. Trends Neurosci. (2004) 27:561-568.
45. QUIK M, VAILATI S, BORDIA T et al.: Subunit composition of nicotinic receptors in monkey striatum: effect of treatments with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine or L-DOPA. Mol. Pharmacol. (2005) 67:32-41.
46. COURT J, SPURDEN D, LLOYD S et al.: Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: α-bungarotoxin and nicotine binding in the thalamus. J. Neurochem. (1999) 73:1590-1597.
47. SILVER AA, SHYTLE RD, PHILIPP MK, WILKINSON BJ, MCCONVILLE B, SANBERG PR: Transdermal nicotine and haloperidol in Tourette's disorder: a double-blind placebo-controlled study. J. Clin. Psychiatry (2001) 62:707-714.
48. SANBERG PR, FOGELSON HM, MANDERSCHEID PZ, PARKER KW, NORMAN AB, MCCONVILLE BJ: Nicotine gum and haloperidol in Tourette's syndrome. Lancet (1988) 1:592.
49. SANBERG PR, SILVER AA, SHYTLE RD et al.: Nicotine for the treatment of Tourette's syndrome. Pharmacol. Ther. (1997) 74:21-25.
50. SANBERG PR, SHYTLE RD, SILVER AA: Treatment of Tourette's syndrome with mecamylamine. Lancet (1998) 352:705-706.
51. DALACK GW, MEADOR-WOODRUFF JH: Smoking, smoking withdrawal and schizophrenia: case reports and a review of the literature. Schizophr. Res. (1996) 22:133-141.
52. FREEDMAN R, HALL M, ADLER LE, LEONARD S: Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol. Psychiatry (1995) 38:22-33.
53. FREEDMAN R, COON H, MYLES-WORSLEY M et al.: Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc. Natl. Acad. Sci. USA (1997) 94:587-592.
54. LEONARD S, BREESE C, ADAMS C et al.: Smoking and schizophrenia: abnormal nicotinic receptor expression. Eur. J. Pharmacol. (2000) 393:237-242.
55. STEINLEIN OK, MULLEY JC, PROPPING P et al.: A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nat. Genet. (1995) 11:201-203.
56. STEINLEIN OK: Neuronal nicotinic receptors in human epilepsy. Eur. J. Pharmacol. (2000) 393:243-247.
57. SCHEFFER IE, BHATIA KP, LOPES-CENDES I et al.: Autosomal dominant frontal epilepsy misdiagnosed as leep disorder. Lancet (1994) 343:515-517.
58. COVEY LS, GLASSMAN AH, STETNER F: Cigarette smoking and major depression. J. Addict. Dis. (1998) 17:35-46.
59. BADIO B, DALY JW: Epibatidine, a potent analgetic and nicotinic agonist. Mol. Pharmacol. (1994) 45:563-569.
60. DECKER MW, CURZON P, HOLLADAY MW et al.: The role of neuronal nicotinic acetylcholine receptors in antinociception: effects of ABT-594. J. Physiol. Paris (1998) 92:221-224.
61. BERNIK TR, FRIEDMAN SG, OCHANI M et al.: Pharmacological stimulation of the cholinergic antiinflammatory pathway. J. Exp. Med. (2002) 195:781-788.
62. 7 subunit is an essential regulator of inflammation. Nature (2003) 421:384-388.
63. JICK H, WALKER AM: Cigarette smoking and ulcerative colitis. N. Engl. J. Med. (1983) 308:261-263.
64. GUSLANDI M: Nicotine treatment for ulcerative colitis. Br. J. Clin. Pharmacol. (1999) 48:481-484.
65. THOMAS GA, RHODES J, GREEN J: Nicotine and gastrointestinal disease. QJM (1996) 89:485-488.
66. GALEAZZI F, BLENNERHASSETT PA, QIU B, O'BYRNE PM, COLLINS SM: Cigarette smoke aggravates experimental colitis in rats. Gastroenterology (1999) 117:877-883.
67. THOMAS GA, RHODES J, GREEN JT, RICHARDSON C: Role of smoking in inflammatory bowel disease: implications for therapy. Postgrad. Med. J. (2000) 76:273-279.
68. MCGEHEE DS, HEATH MJ, GELBER S, DEVAY P, ROLE LW: Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science (1995) 269:1692-1696.
69. GRAY R, RAJAN AS, RADCLIFFE KA, YAKEHIRO M, DANI JA: Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature (1996) 383:713-716.
70. BUNNELLE WH, DECKER MW: Neuronal nicotinic acetylcholine receptor ligands as potential analgesics. Expert Opin. Ther. Patents (2003) 13:1003-1021.
71. TOMA L, BARLOCCO D, GELAIN A: Neuronal nicotinic acetylcholine receptor agonists. Expert Opin. Ther. Patents (2004) 14:1029-1040.
72. 7 subtype. Neurosci. Lett. (1996) 213:201-204.
73. 3A) and nicotinic acetylcholine receptors: the anomalous binding properties of nicotine. Biochem. (2002) 41:10262-10269.
74. BEERS WH, REICH E: Structure and activity of acetylcholine. Nature (1970) 228:917-922.
75. SHERIDAN RP, NILAKANTAN R, DIXON JS, VENKATARAGHAVAN R: The ensemble approach to distance geometry: application to the nicotinic pharmacophore. J. Med. Chem. (1986) 29:899-906.
76. HOLLADAY MW, DART MJ, LYNCH JK: Neuronal nicotinic acetylcholine receptors as targets for drug discovery. J. Med. Chem. (1997) 40:4169-4194.
77. GLENNON RA, HERNDON JL, DUKAT M: Epibatidine-aided studies toward definition of a nicotine receptor pharmacophore. Med. Chem. Res. (1994) 4:461-473.
78. SCHMITT JD: Exploring the nature of molecular recognition in nicotinic acetylcholine receptors. Curr. Med. Chem. (2000) 7:749-800.
79. NICOLOTTI O, ALTOMARE C, PELLEGRINI-CALACE M, CAROTTI A: Neuronal nicotinic acetylcholine receptor agonists: pharmacophores, evolutionary QSAR and 3D-QSAR models. Curr. Topics Med. Chem. (2004) 4:335-360.
80. 2 nicotinic acetylcholine (nACh) receptor pharmacophore models. Curr. Topics Med. Chem. (2004) 4:631-644.
81. 2 nACh receptor pharmacophore models. Bioorg. Med. Chem. Lett. (2004) 19:1841-1844.
82. TONDER JE, OLESEN PH, HANSEN JB, BEGTRUP M, PETTERSSON I: An improved nicotinic pharmacophore and a stereoselective CoMFA-model for nicotinic agonists acting at the central nicotinic acetylcholine receptors. J. Comput. Aided Mol. Des. (2001) 15:247-258.
83. 7 nicotinic acetylcholine receptor. J. Med. Chem. (2000) 43:4045-4050.
84. 3 receptor. Eur. J. Pharmacol. (2002) 452:137-144.
85. 7 nicotinic receptor partial agonist. I. Binding profile and in vitro functional characterization. Soc. Neurosci. Meeting (2004) Abst. 583.1.
86. 7 nicotinic receptor partial agonist. II. Effects in models predictive of therapeutic activity on cognitive symptoms of Alzheimer's disease. Soc. Neurosci. Meeting (2004) Abst. 583.2.
87. 7 nicotinic receptor partial agonist. III. Effects in models predictive of therapeutic activity on cognitive symptoms of schizophrenia. Soc. Neurosci. Meeting (2004) Abst. 583.3.
88. 7 nicotinic acetylcholine receptors in vitro and in vivo. Soc. Neurosci. Meeting (2004) Abst. 583.4.
89. 7 nicotinic acetylcholine receptor agonist, attenuates deficits in step - through passive avoidance and prepulse inhibition in rats. Soc. Neurosci. Meeting (2004) Abst. 435.13.